Each year, more and more Americans will hear the words, “You have pancreatic cancer.”
The American Cancer Society’s estimates for pancreatic cancer in the United States for 2022 are:
Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. It is one of the most deadly cancers with a 5-year survival rate of 11%.
It is slightly more common in men than in women. [American Cancer Society]
Pancreatic Cancer is a formidable disease, recently rising to the 3rd leading cause of cancer death in the United States. There are no early detection tools. In spite of the number of people affected by this disease and a staggering mortality rate that is higher than all other major cancers, research funding is shockingly inadequate. Pancreatic Cancer initiatives receive less than 3% of the National Cancer Institute’s (NCI) research budget.
Funding from organizations like ours is critical for key progressive research and treatment initiatives.
Our mission is to both raise money for pancreatic cancer research and patient programs, as well as make people aware of the funding needs.
Much of our funding to date has been directed towards funding conceptual, out-of-the-box translational research at Jefferson University Sidney Kimmel Cancer Center – an NCI-designated facility and to Fox Chase Cancer Center. Other funding has been directed to patient programs and patient support at both Jefferson and St. Luke’s Cancer Center at St. Lukes’s Upper Bucks Campus, located in our direct community.
